The signal was buried in noise until researchers looked closer.
For decades, the misfolded protein alpha-synuclein has been suspected as a key architect of Parkinson's disease, spreading through the nervous system and eroding the machinery of movement. Now, a closer analysis of an international phase II trial suggests that prasinezumab, a monoclonal antibody designed to intercept that protein, may meaningfully slow motor decline — but only in those patients whose disease is advancing most aggressively. The finding does not yet constitute a cure or even a universal treatment, but it marks a moment when a long-theoretical approach to Parkinson's begins to show its first credible footing in human evidence.
- Parkinson's disease has lacked any treatment capable of slowing its underlying biological progression, leaving patients and researchers in a race against a process they could observe but not interrupt.
- Prasinezumab, tested in the PASADENA phase II trial, showed only modest overall effects at first — but a deeper look revealed a sharper benefit hiding within a specific subgroup of rapidly deteriorating patients.
- Patients with a diffuse malignant phenotype or those already on monoamine oxidase B inhibitors — both markers of fast-moving disease — showed measurably slower motor decline on clinician-rated assessments when given the drug.
- A critical methodological tension emerged: clinician observation detected drug effects that patient self-reporting missed, raising questions about how future trials should be designed to capture true benefit.
- Researchers are urging caution, calling for longer studies and additional randomized trials before prasinezumab can be considered validated — particularly for patients whose disease progresses more slowly.
Parkinson's disease has long been understood to involve the misfolding and spread of a protein called alpha-synuclein, which accumulates inside neurons and drives the progressive loss of motor control. For years, researchers have pursued drugs capable of targeting this protein directly. A new analysis of the PASADENA phase II trial suggests that prasinezumab, a monoclonal antibody designed to neutralize alpha-synuclein, may finally deliver on that promise — though with an important caveat: the benefit appears concentrated in patients whose disease is advancing most rapidly.
The PASADENA trial assigned early-stage Parkinson's patients to receive a placebo, a lower dose of prasinezumab, or a higher dose, while excluding those already on standard dopamine therapies to isolate the drug's biological effect. When the original results were published, the drug showed only modest motor-slowing benefits overall. But when researchers examined patients with markers of rapid progression — those with a diffuse malignant phenotype or already using monoamine oxidase B inhibitors — the drug's effect on clinician-rated motor assessments became considerably more pronounced.
The study also surfaced a methodological insight: objective clinical measurements appeared to detect the drug's effects earlier and more reliably than patient self-reports, suggesting that future trials may need longer timelines or more sensitive outcome measures to capture the full picture.
What remains unresolved is whether prasinezumab offers meaningful benefit to patients with slower-progressing disease, and whether these findings will hold in larger, longer studies. The researchers were deliberate in their restraint, calling for extended observation and additional trials before drawing firm conclusions. Still, for a field that has long theorized about alpha-synuclein as a therapeutic target, this analysis offers the first substantive evidence that the approach may work — at least for those who need it most urgently.
Parkinson's disease destroys neurons in ways that are still not fully understood, but researchers have long suspected that a misfolded protein called alpha-synuclein plays a central role—clumping inside cells, spreading from neuron to neuron, and driving the progressive loss of motor control that defines the disease. For years, the hunt has been on for a drug that could slow or stop that cascade. A new analysis of data from a large international trial suggests that prasinezumab, a monoclonal antibody designed to target and neutralize alpha-synuclein, may finally offer some of that promise—at least for patients whose disease is advancing rapidly.
The evidence comes from a closer look at results from the PASADENA study, a phase II clinical trial that tested prasinezumab against placebo in early-stage Parkinson's patients. When researchers first published the main results, the drug showed a modest slowing of motor decline compared to placebo, but the effect was not uniform across all patients. Some people benefited more than others. The question that lingered was whether the drug might be more effective in a specific subset—those whose disease was moving fastest. To answer that, an international team of researchers dug into the data and examined what happened in patients who showed signs of rapid progression at the start of the trial.
The trial itself was straightforward in design. Patients were randomly assigned to receive either a placebo, a lower dose of prasinezumab (1,500 milligrams), or a higher dose (4,500 milligrams). Researchers stratified participants by age, sex, and whether they were already taking a Parkinson's medication called a monoamine oxidase B inhibitor. Importantly, patients who were already on dopamine agonists or levodopa—the standard symptomatic treatments for Parkinson's—were excluded from the main analysis, to keep the focus on the drug's effect rather than on symptom management.
What the researchers found was striking in its specificity. When they looked at patients who had markers of rapid disease progression—those with what clinicians call a diffuse malignant phenotype, or those already using monoamine oxidase B inhibitors—prasinezumab slowed the worsening of motor symptoms more noticeably than placebo did. The measurement that mattered most was the clinician-rated portion of the Movement Disorder Society Unified Parkinson's Disease Rating Scale, a standard tool that tracks things like tremor, rigidity, and the ability to move. In patients with rapidly advancing disease, this score worsened more slowly in those who received the drug.
The finding raises an important methodological point. The researchers noted that clinician-rated motor assessments seemed to pick up changes faster than patient-reported measures did, suggesting that objective clinical observation may be more sensitive to early drug effects than what patients themselves report. That matters because it means future trials may need to be longer or more carefully designed to catch the full benefit of a treatment like prasinezumab.
What remains unclear is whether prasinezumab will help patients whose disease is progressing more slowly, or whether the benefits seen in this rapidly progressing group will hold up in larger, longer studies. The researchers were careful not to overstate their findings. They called for extended observation periods and additional randomized trials to validate what they found. The drug does not appear to work equally well for everyone, and understanding why—and for whom it works best—will be crucial before it can be considered a standard treatment.
For now, the study offers a measured but genuine glimmer of hope. Alpha-synuclein targeting has been a theoretical promise in Parkinson's research for years. Prasinezumab is one of the first drugs to show that the promise might be real, at least in a subset of patients. The next phase will be to confirm these results and to understand whether this approach can be refined further—perhaps by identifying patients most likely to benefit before treatment begins, or by developing next-generation antibodies that work even better.
Notable Quotes
Prasinezumab could potentially be used to slow the progression of motor-associated degeneration in patients with the rapidly progressing form of Parkinson's disease— Research team, Nature Medicine study
More extended observation periods are required to observe the impact of prasinezumab treatment in patients with the slowly progressing form of the disease— Research team conclusion
The Hearth Conversation Another angle on the story
Why does it matter that the drug worked better in rapidly progressing patients than in the overall trial population?
Because it tells us the drug isn't a dead end—it's just that the signal was buried in noise. When you mix fast progressors with slow progressors, the slow ones drag down the average benefit. Looking at just the rapid progressors lets you see what the drug can actually do.
But doesn't that risk overstating the benefit? Couldn't the rapid progressors just be a lucky subgroup?
That's exactly why they're calling for more trials. This is exploratory analysis, not proof. But the fact that the benefit showed up in patients with specific markers of rapid disease—not just random chance—makes it more plausible that it's real.
What's a diffuse malignant phenotype?
It's a clinical pattern where Parkinson's hits hard and fast across multiple systems—motor and non-motor symptoms both progressing quickly. It's one of the worst presentations you can have.
So the drug helped the sickest patients most?
The ones progressing fastest, yes. Whether that's because they had more room to show improvement, or because the drug genuinely works better when the disease is aggressive, we don't know yet.
Why exclude patients already on levodopa?
Levodopa masks motor symptoms. If you're trying to see whether a disease-modifying drug actually slows the underlying degeneration, you need patients where the decline is visible and not being artificially suppressed by symptom relief.
What happens next?
Longer trials. Bigger trials. And probably a hard look at whether you can predict upfront which patients will benefit, so you're not giving the drug to everyone when it might only help a subset.